Cargando…

Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

SIMPLE SUMMARY: MET amplification is one of the resistance determinants after EGFR-TKI therapy in EGFR mutant NSCLC. In this study, we evaluated the emergence of MET amplification after EGFR-TKI treatment failure. The median progression-free survival associated with the most recent EGFR-TKI treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Beung-Chul, Lee, Ji Hyun, Kim, Min Hwan, Pyo, Kyoung-Ho, Lee, Choong-kun, Lim, Sun Min, Kim, Hye Ryun, Cho, Byoung Chul, Hong, Min Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234556/ https://www.ncbi.nlm.nih.gov/pubmed/34205733 http://dx.doi.org/10.3390/cancers13123096

Ejemplares similares

Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
por: Ahn, Beung-Chul, et al.
Publicado: (2023)

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
por: Hong, Min Hee, et al.
Publicado: (2019)

Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
por: Ahn, Beung-Chul, et al.
Publicado: (2019)

Predicting treatment outcomes using (18)F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
por: Kim, Chang Gon, et al.
Publicado: (2022)

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma
por: Kim, Seok-Young, et al.
Publicado: (2019)

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
por: Lim, Sun Min, et al.
Publicado: (2016)

Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Jeong, Jae-Heon, et al.
Publicado: (2013)

Amplification of distinct α-synuclein fibril conformers through protein misfolding cyclic amplification
por: Jung, Byung Chul, et al.
Publicado: (2017)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

Alteration status and prognostic value of MET in head and neck squamous cell carcinoma
por: Cho, Yoon Ah, et al.
Publicado: (2016)

Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
por: Kim, Min Hwan, et al.
Publicado: (2020)

SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models
por: Synn, Chun‐Bong, et al.
Publicado: (2021)

Correction: Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
por: Kim, Min Hwan, et al.
Publicado: (2020)

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma
por: Catenacci, Daniel V. T., et al.
Publicado: (2016)

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Lee, Jae Cheol, et al.
Publicado: (2013)

Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial
por: Park, Hye Jung, et al.
Publicado: (2021)

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
por: Hartmaier, Ryan J., et al.
Publicado: (2023)

Prognostic implications of PD-L1 expression in patients with angiosarcoma
por: Lee, Jii Bum, et al.
Publicado: (2021)

No Evidence for Association between Tyrosine Hydroxylase Gene Val81Met Polymorphism and Susceptibility to Tardive Dyskinesia in Schizophrenia
por: Lee, Heon-Jeong, et al.
Publicado: (2009)

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
por: Pyo, Kyoung-Ho, et al.
Publicado: (2020)

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
por: Kwon, Byoung Soo, et al.
Publicado: (2020)

Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer
por: Cho, Jae-Won, et al.
Publicado: (2020)

Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report
por: Wang, Chang-guo, et al.
Publicado: (2018)

PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma
por: Kim, Hyo Song, et al.
Publicado: (2016)

EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
por: Hwangbo, Won, et al.
Publicado: (2013)

Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
por: Lim, Sun Min, et al.
Publicado: (2022)

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
por: Sang, Yun Beom, et al.
Publicado: (2022)

De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
por: Li, Jing-Wen, et al.
Publicado: (2019)

The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
por: Park, Seong Yong, et al.
Publicado: (2020)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
por: Kim, Eun-Young, et al.
Publicado: (2013)

Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate
por: Suh, Jee Won, et al.
Publicado: (2019)

Role and Function of O-GlcNAcylation in Cancer
por: Lee, Jii Bum, et al.
Publicado: (2021)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
por: Han, Ji-Youn, et al.
Publicado: (2017)

Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells
por: Kang, Minyong, et al.
Publicado: (2017)

Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer
por: Yang, Jiangping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t82belo5p31jpdopv6fphbvuhr